Q1 The issue of over pricing zidovudine is a desirous issue for Burroughs Wellcome Company consequently causing forbid promotional material and the fears in my opinion be well founded as furthest as BWs hereafter AIDS medicates and drugs for other diseases (Zovirax and Sudafed) are concerned. Within the present-day(prenominal) AZT market, the central consumers are AIDS and human immunodeficiency virus patients in need of treatment. AZTs role to the patients is paramount; terminuss show AZT extends patients vivification expectancy, increase their sense of wellness, boost their immune system, and military service with charge gain. Clearly the benefits of AZT have a beam force on the patients quality of life; as a result patients desire for the treatment is high. And thats the reason why the negative advancement wont impact the current sales of AZT in the absence seizure of any embossments (at present AZT is the however treatment operational for HIV). However, whe n it comes to other 2 products (Zovirax and Sudafed) and any emf AIDS drug that BW might invent / walk out in the future the situation is quite different. The backlash would stir the customers emotional response . This would affect how a consumer thinks about a club and smatter to others about it. The negative publicity would light BWs reputation with its customers, pave the way for the sale of substitute products by competitors.
The customers would also win over their role from being apostles to detractors thus telling others how bad the company is and why they should not procure BWs products. Thus this could be sc ourge to the BWs business affecting its foo! l image. Based on our five forces analysis, the effort is moderately lovely with the significant threats coming from possible substitute products and rivalry from say competitors. Assuming that there are telling substitutes (which are either priced equally or... If you want to get a full essay, tell apart it on our website:
OrderCustomPaper.comIf you want to get a full essay, visit our page: write my paper
No comments:
Post a Comment